Quick answers
- What is Ranibizumab-eqrn used for?
- The FDA-approved label (Lucentis, Genentech, Inc., November 21, 2025) says: “LUCENTIS is indicated for the treatment of patients with: LUCENTIS, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) Macular Edema Following Retinal Vein Occlusion (RVO) Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) Myopic Choroidal Neovascularization (mCNV) 1.1 Neovascular (Wet) Age-Related …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Ranibizumab-eqrn have a boxed warning?
- The label we quote has no boxed warning, but 1 of 6 FDA labels for this medicine do. Check the label of your own product.
- Is there a shortage of Ranibizumab-eqrn?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Ranibizumab-eqrn been recalled?
- FDA enforcement reports list 1 recall of products of this medicine; the newest started October 18, 2022 (Class III). A recall usually concerns specific lots, not every product.
- Who makes Ranibizumab-eqrn?
- 6 companies list prescription products of Ranibizumab-eqrn in the FDA NDC Directory, including Genentech, Inc., Sandoz Inc and Zydus Pharmaceuticals USA Inc..
What Ranibizumab-eqrn is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
LUCENTIS is indicated for the treatment of patients with: LUCENTIS, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) Macular Edema Following Retinal Vein Occlusion (RVO) Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) Myopic Choroidal Neovascularization (mCNV) 1.1 Neovascular (Wet) Age-Related …
— FDA label: Lucentis, Genentech, Inc., effective November 21, 2025. Read the full label on DailyMed →
The FDA has 6 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
1 of 6 FDA labels for this medicine have a boxed warning.
Forms and how it is given
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Genentech, Inc.3 products
- Sandoz Inc2 products
- Zydus Pharmaceuticals USA Inc.2 products
- Coherus BioSciences Inc2 products
- Biogen Inc.1 product
- Harrow Eye, LLC1 product
FDA approval history
- BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| BLA125156 LUCENTIS | Genentech | June 30, 2006 | 17, latest February 15, 2024 2024: Labeling · 2018: Manufacturing (CMC) · 2017: Efficacy |
| BLA761165 CIMERLI | Sandoz Inc | August 2, 2022 | 1, latest May 21, 2024 2024: Bioequivalence |
| BLA761197 SUSVIMO | Genentech Inc | October 22, 2021 | 4, latest September 5, 2025 2025: Labeling · 2025: Efficacy · 2025: Efficacy |
| BLA761202 BYOOVIZ | Samsung Bioepis Co Ltd | September 17, 2021 | 9, latest September 4, 2026 2026: Manufacturing (CMC) · 2026: Labeling · 2026: Labeling |
| BLA761473 NUFYMCO | Formycon AG | December 18, 2025 | — |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
October 18, 2022 · Class III · Terminated · D-0025-2023
Defective Delivery System: Commercial implants do not meet the filed specification for the intended use, a few patients have experienced an issue with the implants that renders it non-functioning.
Susvimo (ranibizumab injection), 100mg/mL, sold together as a) carton containing One Susvimo single-dose vial and One Susvimo initial fill needle, NDC 50242-078-55; and b) carton labeled as Susvimo Ocular Implant with In — Genentech Inc
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 1864423, 1864425, 2045501, 2045502, 2584857, 2584863, 2602353, 2602359, 2612675, 2612681 … (+2) |
|---|---|
| SPL set ID of the quoted label | de4e66cc-ca05-4dc9-8262-e00e9b41c36d |
| FDA labels (SPL) | 6 |
| FDA applications | BLA125156, BLA761165, BLA761197, BLA761202, BLA761473 |
| Active ingredients (FDA) | RANIBIZUMAB |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Lucentis, Genentech, Inc., effective November 21, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →